evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

186 questions · 190 findings · 17 reviews · Haematology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 47 · 24.7%GRADE not reported 21 · 11.1%Very low 26 · 13.7%Low 47 · 24.7%Moderate 37 · 19.5%High 12 · 6.3%

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Mortality Median · patients with primary CNS lymphoma

Cytarabine plus high‐dose methotrexate showed no clear difference in mortality (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).

1 finding from 1 review

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Progression/relapse · patients with primary CNS lymphoma

Cytarabine plus high‐dose methotrexate probably leads to lower progression/relapse (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).

1 finding from 1 review

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Treatment‐related mortality · patients with primary CNS lymphoma

Cytarabine plus high‐dose methotrexate showed no clear difference in treatment‐related mortality compared with high‐dose methotrexate alone (moderate certainty).

1 finding from 1 review

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

Severe adverse effects (grade 3+): Infection · patients with primary CNS lymphoma

Cytarabine plus high‐dose methotrexate probably leads to higher infections (grade 3 to 4) compared with high‐dose methotrexate alone (moderate certainty).

1 finding from 1 review